|
Medier: |
Investorer: |
|
|
|
|
Elin K. Hansen |
Mads Veggerby Lausten |
|
Tlf.: 4442 3450 |
Tlf.: 4443 7919 |
|
|
|
|
|
Hans Rommer |
|
|
Tlf.: 4442 4765 |
|
|
Storaktionærmeddelelse
| Source: Novo Nordisk A/S
Novo Nordisk skal hermed i henhold til Værdipapirhandelslovens § 29 meddele, at Capital Group Companies den 3. oktober 2007 har oplyst til Novo Nordisk, at Capital Group Companies nu besidder 48.647.641 stk. B-aktier a 2 kr., hvilket svarer til 15,04% af den samlede aktiekapital i Novo Nordisk.
Yderligere information:
Fondsbørsmeddelelse nr. 27 / 2007
Recommended Reading
-
Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.
Read More -
Today, the Supreme People’s Court in China made a positive decision concerning the intellectual property rights relating to the semaglutide compound patent
Read More